	US 12,324,830 B2
	*Methods of treatment for Candida auris* infections**
John E. Edwards, Jr., Palos Verdes Estates, CA (US); Shakti Singh, Carson, CA (US); Ashraf S. Ibrahim, Irvine, CA (US); and Priya Uppuluri, Torrance, CA (US)
Appl. No. 17/046,169
Filed by LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER, Torrance, CA (US)
PCT Filed Apr. 10, 2018, PCT No. PCT/US2018/026889 § 371(c)(1), (2) Date Oct. 8, 2020, PCT Pub. No. WO2019/199279, PCT Pub. Date Oct. 17, 2019.
Prior Publication US 2021/0030852 A1, Feb. 4, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 31/10 (2006.01); C07K 16/14 (2006.01)

CPC A61K 39/0002 (2013.01) [A61K 39/39575 (2013.01); A61K 45/06 (2013.01); A61P 31/10 (2018.01); C07K 16/14 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01)]

14 Claims

1. A method of treating a subject for, immunizing a subject against, preventing in a subject, or inducing production of antibodies in a subject against, a Candida auris infection by administering to the subject an immunogenic amount of a C. auris Als3 polypeptide comprising at least one of SEQ ID NOs: 1-7, or an anti-C. auris Als3 antibody.